TScan Therapeutics (TCRX) Research & Development (2020 - 2025)
Historic Research & Development for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to $31.7 million.
- TScan Therapeutics' Research & Development rose 2066.48% to $31.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $123.5 million, marking a year-over-year increase of 2297.07%. This contributed to the annual value of $107.4 million for FY2024, which is 2177.69% up from last year.
- According to the latest figures from Q3 2025, TScan Therapeutics' Research & Development is $31.7 million, which was up 2066.48% from $32.6 million recorded in Q2 2025.
- TScan Therapeutics' Research & Development's 5-year high stood at $32.6 million during Q2 2025, with a 5-year trough of $7.3 million in Q1 2021.
- In the last 5 years, TScan Therapeutics' Research & Development had a median value of $21.8 million in 2023 and averaged $20.8 million.
- Its Research & Development has fluctuated over the past 5 years, first surged by 14438.33% in 2021, then surged by 580.74% in 2022.
- TScan Therapeutics' Research & Development (Quarter) stood at $12.6 million in 2021, then increased by 23.76% to $15.6 million in 2022, then skyrocketed by 43.59% to $22.4 million in 2023, then soared by 31.01% to $29.4 million in 2024, then increased by 7.95% to $31.7 million in 2025.
- Its last three reported values are $31.7 million in Q3 2025, $32.6 million for Q2 2025, and $29.8 million during Q1 2025.